Harvard University Researchers Show Specially Formulated High EPA Omega-3 Supplement Effective as a Stand-Alone Treatment for Children with Bipolar Disorder, ADD
4/4/2007 12:48:45 PM
BOSTON--(BUSINESS WIRE)--A recently published study by researchers at Harvard’s Massachusetts General Hospital shows that a specially formulated high EPA Omega-3 fatty acid supplement should be the first-line treatment for children with ADD, ADHD, bipolar disorder, and other educational and behavioral problems. The OmegaBrite™ supplement of Omega-3 fatty acids was tested for effectiveness and safety on 20 boys and girls with bipolar disorder, 6 to 17 years old, over an eight-week period. Half of these participants experienced a rapid 30 percent reduction in symptoms with no side effects.